lished as an effective and curative therapy for idiopathic ventricular tachycardia (I-VT). [1] [2] [3] [4] [5] [6] [7] [8] It is well known that some I-VTs can be eliminated by RFCA at the endocardium of the left ventricular outflow tract (LVOT) or the left sinus of Valsalva (LSV). [1] [2] [3] 8 However, some that arise from the epicardial portion of the LVOT are remote from the LSV or left ventricular (LV) endocardium and are not amenable to ablation at those sites. 5, 8, 9 Several recent reports have demonstrated that I-VTs arising from the epicardial portion of the LVOT can be ablated from the distal portion of the coronary venous system that lies along the LV epicardial site. [10] [11] [12] [13] However, the ECG and electrophysiologic characteristics of this type of ventricular tachycardia (VT) have not been sufficiently clarified.
(LVOT endocardium) and LSV both preceded the onset of the QRS complex by 16 ms, and RFCA at both sites eliminated the VTs. However, the PVCs, which had the same QRS morphology as the first beat of the clinical VT and PVCs, recurred a few hours after the ablation procedure. Although sporadic PVCs occurred (404 beats/day), he was asymptomatic and did not receive medications.
Three years later at the age of 30 in 2006, he began to experience palpitations and the sensation of a pulse deficit. The 12-lead ECG at the time of admission demonstrated regular sinus rhythm with a narrow QRS complex and a normal axis (Fig 1) . During the clinical arrhythmia, the surface ECG always revealed monomorphic VT or PVCs with a left bundle-branch block morphology and an inferior axis, which had the same QRS morphology as those occurring 3 years ago. Holter ECG monitoring revealed a nonsustained VT lasting up to 34 consecutive beats and a total number of PVCs consisting of 41,691 beats/day. Echocardiography disclosed a dilated LV with an end-diastolic internal dimension of 57 mm and a decreased LV wall motion with an ejection fraction of 39% during sinus rhythm. The chest X-ray revealed a cardiothoracic ratio of 51.2%, and the plasma level of brain natriuretic peptide (BNP) was 30 pg/ml (normal reference values in Japanese are <18.4 pg/ml).
After informed written consent was given, a second electrophysiology study was performed. Under the fluoroscopic guidance, multielectrode catheters were inserted percutaneously into the femoral veins and positioned at the high right atrium, right ventricular (RV) apex, RV and LVOTs. Mapping within the coronary venous system was performed using a 2-Fr octapolar electrode catheter (Pathfinder ® , Cardima, Fremont, CA, USA) that was positioned around the transitional area from the distal portion of the GCV to the proximal portion of the anterior interventricular vein (AIV; Fig 2) . 9 In the coronary venous system, the GCV runs anteriorly in the atrioventricular sulcus and descends as the AIV near the bifurcation of the left main coronary artery in the interventricular sulcus, parallel to the left anterior descending coronary artery. 14, 15 In this case, the site where the body of the electrode catheter was bent acutely at the anterobasal portion of the heart in the left anterior oblique projection was considered to be located at the boundary of the transition from the GCV to the AIV (arrows; Fig 2) . A 7-Fr quadripolar catheter with a 4-mm distal electrode, embedded thermistor, interelectrode spacing of 2-5-2 mm, and deflectable tip was used for mapping and ablation (Celsius ® , Biosense Webster, Diamond Bar, CA, USA; Blazer II ® , EP Technologies, San Jose, CA, USA).
At baseline, clinical PVCs and VT occurred spontaneously, and activation mapping and pace mapping were performed. The earliest ventricular activation during the clinical arrhythmia was found in the GCV (coronary sinus (CS) 5-6 and CS 6-7 in Fig 3A) and LVOT endocardium, which preceded the onset of the QRS complex by 30 ms (Fig 3A) . We attempted to ablate the arrhythmia from the LVOT endocardium, as in the first electrophysiology study session. The QRS morphology during pacing from that site was not identical to that during the PVCs or VT (Fig 4A) . Applying RF energy at that site using a maximum power of 50 W and maximum electrode -tissue interface temperature of 60°C during the VT terminated it 5.5 s after commencing the application of the RF energy. After the ablation from the LVOT endocardium, less VT or PVCs occurred than before the RFCA. However, a clinical VT lasting for 40 s appeared during isoproterenol infusion (1.0 g/min), and it was terminated by burst pacing from the RV apex. With additional mapping, a site with local ventricular activation that preceded the onset of the QRS complex by 27 ms was found in the LSV (Figs 2B,3B ). Perfect pace mapping was not obtained during pacing from that site either (Fig 4B) . After RF application at that site using a maximum power of 35 W and maximum electrode -tissue interface temperature of 55°C, the clinical VT could no longer be induced by burst pacing from the RV apex or by isoproterenol infusion. However, the clinical PVCs were still induced reproducibly with burst pacing.
Because the PVCs could not be abolished by RF application from either the LVOT endocardium or LSV, we attempted to ablate the PVCs from within the coronary venous system. A 5-Fr, deflectable catheter with a 5-mm distal tip (Ablaze ® , Japan Lifeline Co, Ltd, Tokyo, Japan) was advanced through the coronary sinus to the GCV. During detailed mapping within the coronary venous system, a 
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site where the local ventricular activation during the clinical PVCs that preceded the onset of the QRS complex by 32 ms was found in the GCV (Fig 3C) . A unipolar recording at that site demonstrated an rS pattern, consisting of an initial tiny positive deflection and subsequent steep negative deflection ( Fig 3C) . That site corresponded to electrode number 6 of the 2-Fr octapolar electrode catheter in the GCV (Fig 2C) . Pace mapping was not attempted from that site. Under a setting of a maximum electrode -tissue interface temperature of 55°C, RF energy application was attempted. The power was increased gradually from an initial setting of 5 W. The application of RF energy was 60 s in duration. The maximum power delivered was 17 W, and the maximum electrode -tissue interface temperature was 56°C. The initial and average impedance during the RF energy applications was 150 and 130 ohms, respectively. No VT or PVCs were inducible after RFCA at that site, even with an isoproterenol infusion (1.0 g/min) or extensive programmed stimulation from the RV. The distance from the catheter tip to the left anterior descending coronary artery or left circumflex artery was approximately 12 mm, as observed on biplane fluoroscopy. Repeat coronary angiography revealed that there was no narrowing of the coronary arteries and that the coronary veins were patent. No complications occurred during or after the ablation procedure, and the patient was discharged with no need for medication. Three months later, echocar- Table 1 .
Table 2 ECG Characteristics of 10 Cases of I-VT Arising From the Epicardial Portion of the LVOT

In the QRS morphology, the letters Q, R, S refer to relatively high amplitude waves (>5 mm). Conversely, q, r, s refer to relatively low-amplitude waves (≤5 mm). The R-wave duration index was calculated by dividing the QRS complex duration by the longer R-wave duration in lead V1 or V2. 7 The R/S-wave amplitude ratio for leads V1 and V2 was calculated as the amplitude of the QRS complex peak or nadir to the isoelectric line. 7 The R/S-wave amplitude index was calculated as the greater value of the R/S-wave amplitude ratio in lead V1 or V2. 7 The maximum duration index (MDI) was calculated by dividing the QRS complex duration by the earliest time to the maximum deflection in any of the precordial leads. 12 LV, left vantricular; Q-wave ratio (aVL/aVR), the ratio of the Q-wave amplitude in aVL to aVR; TZ, transition zone of precordial leads; LV epi, LV epicardium of the LVOT remote from the LSV; LV end, endocardium of the LVOT. Other abbreviations see in
diography disclosed that the LV performance had improved with an end-diastolic internal dimension of 52 mm and ejection fraction of 55%. The cardiothoracic ratio decreased to 47% and the plasma level of BNP decreased to 10.2 pg/ml. Three sessions of Holter ECG monitoring during the followup period revealed no VT or PVCs. The patient has done well with no recurrence of VT or PVCs during a 10-month follow-up period.
Literature Review
Selected features of 20 cases of I-VTs being ablated from the coronary venous system or by a percutaneous epicardial approach [10] [11] [12] [13] and of the present case are summarized in Table 1 . In 10 of these cases, the 12-lead ECG of the I-VTs was available, and some data were obtained or measured from the magnified illustrations of the 12-lead ECGs and intracardiac electrograms ( Table 2 ). There were 10 men and 10 women, and the mean age was 46±19 years old (range, 11-74). All had VT as well as PVCs, and none had structural heart disease. The successful ablation site was in the AIV in 5 patients, GCV in 4, GCV-AIV in 8, and middle cardiac vein in the remaining 3. The maximum power of the RF energy was 5-20 W, and the maximum electrode -tissue interface temperature was 55-60°C. In 17 cases of I-VTs arising from the epicardial portion of the OT (Patient Nos. 1-11, 15-20 in Table 1 ), the local ventricular activation during the arrhythmias preceded the onset of the QRS complex by 20±16 ms (range, 3-30 ms), at either of the sites on the endocardium of the RVOT or LVOT, and LSV. However, the earliest ventricular activation was recorded within the distal portion of the coronary venous system, and it preceded the onset of the QRS complex by 40±7 ms (range, 0-65 ms).
In the analysis of the 12-lead ECGs during the arrhythmias obtained from 10 patients (Table 2) , lead I exhibited an rS, QS, or qs pattern. In 8 patients (80%), an S (s) wave was absent in leads V5 or V6. The transition zone in the precordial leads occurred between leads V1 and V3. In the analysis of leads V1 and V2, the R-wave amplitude index, which was calculated by dividing the QRS complex duration by the longest R-wave duration in leads V1 or V2, 7 was greater than 50% in 8 patients (80%), and the R/S amplitude index, which was calculated as the greatest value of the R/S-wave amplitude ratio measured in leads V1 or V2, 7 was greater than 30% in 8 (80%). The maximum duration index (MDI), calculated by dividing the QRS duration by the earliest time to the maximum deflection in any of the precordial leads, 12 was more than 0.55 in 6 patients (60%). Our algorithm, which was developed for identifying the origin of idiopathic OT tachycardias, 8 identified the origin of the VT in the LSV in 2 patients and in the LV end in 2 patients. In the remaining 6 patients, the origin of the VT was classified as in the LV epicardium, and was defined as a VT that could not be ablated with RFCA from the LSV, despite the earliest ventricular activation being recorded in the LSV. 8 
Discussion
Major Findings
Our case report indicates that when the earliest ventricular activation during the arrhythmia is recorded within the GCV and when complete elimination of the I-VT can not be obtained with RFCA at the LVOT endocardium or LSV, RFCA within the coronary venous system may be curative.
LV Epicardial Tachycardia
It is well known that some I-VTs arising from the epicardial portion of the LVOT can be ablated from the LSV (LSV-VTs). [5] [6] [7] [8] [9] Because the tip temperature should be maintained at <55°C to avoid potential complications, in the case of RFCA in the LSV, 6 the distance between the ablation site within the LSV and origin of the VT should mainly affect the results of the RF ablation from the LSV. Therefore, some I-VTs with the earliest ventricular activation in the LSV cannot be ablated from the LSV because of the distance from the LSV, and those VTs are thought to originate from the LV epicardium around the GCV or the AIV. 5 Those I-VTs have been considered as possible to ablate through the coronary venous system or by percutaneous epicardial instrumentation. Recently, several cases of IVTs in which successful elimination was achieved with RFCA from within the distal potion of the coronary venous system (LVEpi-VTs) have been reported. [10] [11] [12] [13] To avoid futile applications of RF energy, and to reduce the possibility of any potential complications from RFCA delivered from the LSV or within the coronary venous system, it is important to assess whether or not the I-VTs can be ablated from the LSV or LVOT endocardium or from the coronary venous system. Therefore, a detailed analysis of the 12-lead ECG and intracardiac electrograms during the arrhythmia are indispensable for predicting the precise origin of I-VTs arising from the LVOT.
From the summarized analysis of 10 LVEpi-VTs (Table2), the ECG characteristics of the LVEpi-VTs seem to be similar to those of the LSV-VTs. An S wave in lead I, deep Q wave in lead aVL, tall R wave in the inferior leads, and precordial transition zone near leads V1-3 have been reported as the ECG findings of I-VTs arising from the LV epicardial portion. 5, 9 An R-wave amplitude index of >50% and an R/S amplitude index >30%, which are calculated using leads V1 and V2, have been reported as useful for predicting LSV-VT. 7 However, these 2 indexes may not be helpful for differentiating an LVEpi-VT from an LSV-VT because most LVEpi-VTs fulfill the criteria for an LSV-VT (Table 2) . 8 In the ECG analysis of 10 patients with LVEpiVTs (Table 2) , all had S(s) waves in lead I, and the precordial transition lead was ≤lead V3. Furthermore, 2 patients had a QS pattern in leads V1 and V2, but the calculated Rwave amplitude index and R/S amplitude index fulfilled the criteria for LSV-VTs in the remaining 8 patients. Therefore, any of the parameters described above do not seem to be useful for differentiating LVEpi-VTs from LSV-VTs. Recently, MDI was reported as a new parameter for identifying LVEpi-VTs. 12 In the 10 summarized patients, an MDI ≥0.55, which may predict LVEpi-VTs, was found in 6 patients (60%). On the other hand, the ECG findings fulfilled the criteria of LVEpi-VTs, which developed recently, 8 in 6 (60%) patients. As a result, 9 (90%) patients fulfilled an MDI ≥0.55 and/or the ECG criteria for LVEpi-VTs. 9, 12 Therefore, in order not to miss any LVEpi-VTs, it should be kept in mind that there is a possibility of the arrhythmia being an LVEpi-VT when the MDI is ≥0.55 or when the ECG findings have fulfilled the criteria for an LVEpi-VT. 8 Furthermore, the absence of an S(s) wave in lead I or a precordial transition lead >lead V3 may eliminate the possibility of it being an LVEpi-VT.
Detailed analysis of the intracardiac electrograms is also useful for diagnosing and ablating LVEpi-VTs. In 12 LVEpi-Circulation Journal Vol.71, December 2007 VTs in which multisite mapping was performed (Table 1) , the earliest ventricular activation during the arrhythmia was always found within the distal portion of the coronary venous system, which was the successful ablation site. A recent study demonstrated that, with a detailed analysis of the intracardiac electrograms recorded from the GCV-AIV and LSV, it may be possible to differentiate the LVEpi-VTs from the LSV-VTs. 9 
Clinical Implications
Based on the summarized data (Tables 1,2) , when there are S(s) waves in lead I, a precordial transitional lead ≤lead V3, R-wave amplitude index >50%, R/S amplitude index >30%, and/or MDI ≥0.55, or when the ECG algorithm matches an LVEpi-VT, there is a fair possibility that the I-VT arises from the distal portion of the coronary venous system. In such a setting, the earliest ventricular activation is always recorded within the coronary venous system. When the earliest ventricular activation is not recorded within the coronary venous system, the possibility of an LVEpi-VT is quite low, and further mapping in the OT should be performed.
RF energy applications within the coronary venous system can be challenging because they can potentially cause complications, such as intramural thrombosis, cardiac tamponade, or coronary artery injury, even if they are performed with relatively low power. 16 Therefore, at present, RF applications should be attempted only when the RF energy application at the LVOT endocardium and LSV results in failure.
Study Limitations
First, some measurement variables obtained from the previous reports were analyzed and calculated from magnified illustrations when there was no description of those measurement variables in the text. Therefore, there may have been some errors. Second, as we did not perform an extensive examination with programmed electrical stimulation or infusion of drugs such as adenosine, the precise mechanism underlying the VT in the present case was not determined.
Conclusions
RFCA within the coronary venous system is effective for eliminating I-VTs arising from the LV epicardial portion in selected patients. RFCA from within the coronary venous system should be performed with much care when RFCA from both the LV endocardium and LSV cannot eliminate the I-VT. Detailed analysis of the ECG and intracardiac recordings may help in diagnosing and ablating I-VTs arising from the LV epicardium.
